Cytokinetics recently announced that MYQORZO (aficamten), a cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy, is now commercially available in the U.S. via ...

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO™ (aficamten) is now available for prescription in 5 mg, 10 mg, 15 ...

LawCrossing has introduced a newly updated comprehensive review database focused on BigLaw summer associate programs, providing law students and early-career professionals with a centralized resource ...

The transfer portal is just warming ahead of its January 2nd official opening, but it's already busy in the Big Ten. While teams like James Madison and North Texas are suffering wholesale devastation, ...

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...

CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...

MINOT — Recently I wrote about Thread, which for years was a start-up darling based in Grand Forks that was showered with state and federal tax dollars. The company, which is now in arrears on its ...

A drone provided by U.S. Army Capabilities Command to simulate an adversary unmanned aerial system, was used as a target at Red Sands 23.2 Live Fire Exercise at Shamal-2 Range in northeastern Saudi ...

Frederick L. Locke, MD, discusses the 2025 removal of the REMS program for CAR T-cell therapy and the resulting improvements to patient access. Frederick L. Locke, MD, chair of the Department of Blood ...

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient ...

Introduction: Mavacamten is a first-in-class cardiac myosin inhibitor approved by the FDA for the treatment of adults with symptomatic New York Heart Association (NYHA) class II–III obstructive ...